Anzeige
Meldung des Tages: Die Bohrer rollen – der Durchbruch-Moment ist da

Quest Diagnostics News

Aktie
WKN:  904533 ISIN:  US74834L1008 US-Symbol:  DGX Land:  USA
164,23 €
-4,85 €
-2,87%
10.04.26
Depot/Watchlist
Marktkapitalisierung *
16,68 Mrd. €
Streubesitz
0,32%
KGV
19,57
Dividende
2,82 EUR
Dividendenrendite
1,93%
Nachhaltigkeits-Score
35 %
Index-Zuordnung
S&P 500

Quest Diagnostics News

25.09.25 - PR Newswire
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025 PR Newswire
23.09.25 - PR Newswire
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-​First Epic Collaboration PR Newswire
22.09.25 - PR Newswire
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-​Surgical Treatment for Lung Cancer PR Newswire
15.09.25 - PR Newswire
Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference
Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference PR Newswire
15.09.25 - LYNX Analysen
Auf der Suche nach einem Dauerläufer?
Quest Diagnostics ist nicht nur eine Hälfte eines Duopols, die Aktie ist auch ein echter Dauerläufer – und das mit gutem Grund. Jetzt vollständige Analyse lesen
04.09.25 - PR Newswire
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering PR Newswire
02.09.25 - PR Newswire
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-​Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index PR Newswire
26.08.25 - PR Newswire
Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan PR Newswire
25.08.25 - PR Newswire
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics PR Newswire
15.08.25 - PR Newswire
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference PR Newswire
13.08.25 - PR Newswire
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics Declares Quarterly Cash Dividend PR Newswire
07.08.25 - PR Newswire
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-​surgical Treatment for Two Cancer Types PR Newswire
05.08.25 - PR Newswire
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care PR Newswire
29.07.25 - PR Newswire
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing PR Newswire
22.07.25 - PR Newswire
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 PR Newswire
15.07.25 - PR Newswire
Quest Diagnostics Introduces Testing for Oropouche Virus
Quest Diagnostics Introduces Testing for Oropouche Virus PR Newswire
09.07.25 - PR Newswire
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Quest Diagnostics to Offer FDA-​Cleared Fujirebio Blood Test for Alzheimer's Disease PR Newswire
25.06.25 - PR Newswire
Quest Diagnostics Releases 2024 Corporate Responsibility Report
Quest Diagnostics Releases 2024 Corporate Responsibility Report PR Newswire
23.06.25 - PR Newswire
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 PR Newswire
10.06.25 - PR Newswire
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
Quest Diagnostics to Develop Multi-​cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology PR Newswire

Newssuche

Videos

newspaper
07.04.26 -4,86%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »